Phd in MOLECULAR MEDICINE

email: ernesto.maddaloni@uniroma1.it
phone:
building: Seconda Clinica Medica
room: Stanza 9

Dr Ernesto Maddaloni, is currently Assistant Professor of Endocrinology and Diabetes at Sapienza University of Rome, Italy. He gained his MD, clinical specialty in Endocrinology and Diabetes and PhD in “Integrated Biomedical Sciences and Bioethics” at Campus Bio-Medico University of Rome. He has joined the Vascular Cell Biology Section of the Joslin Diabetes Center (Harvard Medical School) for a Post-Doctoral Research Fellowship in 2014 and the Diabetes Trial Unit of the University of Oxford in 2017 as a mentee of the European Foundation for the Study of Diabetes (EFSD) Future Leaders Mentorship Program, to actively pursuing his studies on clinical diabetes, cardiovascular outcomes and novel diabetes complications. His research interests focus on the study of adults with autoimmune diabetes and the interplay between vascular complications, bone health and autoimmunity. After the Sars-CoV2 infection outbreak, he has contributed also with original articles evaluating the strict relationship between diabetes and related comorbidities with Covid-19.
Dr Maddaloni has been a study investigator and coordinator for several national and international clinical trials and has published as lead author in several top-ranked peer-reviewed international medical journals (for publication list see: https://www.ncbi.nlm.nih.gov/myncbi/1xGOuoCbV1uAs/bibliography/public/).
His scientific achievements have been recognized with several awards, including the 2015 Albert Renold Fellowship from the European Foundation for the Study of Diabetes, the 2017 (under 32) and 2021 (under 35) Young Investigator Awards from the Italian Society of Endocrinology (SIE), the 2017 Early Investigator Award from the Endocrine Society (USA) and the 2020 Young (under 35) Investigator Award from the Italian Society of Diabetes (SID).


PRESENT POSITION
Assistant Professor (RTDB SC 06/D2, SSD MED13), Faculty of Medicine and Dentistry, Sapienza University of Rome, Italy

DEPARTMENT:
Department of Experimental Medicine

ADDITIONAL APPOINTMENTS
Research Associate, Diabetes Trial Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, UK


EDUCATION AND CAREER
2018 – 2021 Post-doc, Faculty of Medicine and Dentistry, Sapienza University of Rome, Italy
2017 – 2021 Senior Research Fellow, Diabetes Trial Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, UK
2014 – 2015 Post-Doctoral Research Fellowship in Vascular Cell Biology, Joslin Diabetes Center, Harvard Medical School (Supervisor Prof. George L. King)


2019 PhD. Faculty of Medicine and Surgery, Department of Endocrinology, University Campus Bio-medico, Italy
2016 Board Certified. Faculty of Medicine and Surgery, Department of Endocrinology, University Campus Bio-medico, Italy
2010 Master Degree in Medicine and surgery
Faculty of Medicine and Surgery, Department of Endocrinology, University Campus Bio-medico, Italy

MOST RELEVANT RESEARCH LINES
- Clinical and physiopathological characterization of autoimmune diabetes in adults.
- Study of clinical and pathophysiological features of emerging complications of diabetes mellitus.
- Study of the molecular mechanisms in the correlation between bone metabolism and vascular complications of diabetes mellitus.
- Immuno-metabolic and phenotypic characterisation of obesity in autoimmune diabetes, and its consequences

COLLABORATIONS
- Joslin Diabetes Center, Harvard Medical School affiliated (Prof. George King, Prof K Park, Prof Myra Lipes)
- Diabetes Trial Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, UK (Prof. Rury R Holman, Prof Amanda Adler)
- Università Campus Bio-Medico di Roma (prof. P. Pozzilli, Prof. Nicola Napoli).

FIVE SELECTED PUBLICATIONS

Maddaloni E, Xia Y, Park K, D’Eon S, Tinsley LJ, St-Louis R, Khamaisi M, LI Q, King GL, Keenan HA. “High Density Lipoprotein modulates osteocalcin expression in circulating monocytes: a potential protective mechanism for cardiovascular disease in type 1 diabetes.” Cardiovasc Diabetol. Vol. 16, no. 1 pp:116. Sep 2017. doi: 10.1186/s12933-017-0599-2. PMID 28915881

Leanza G, Maddaloni E (first author equal contribution), Pitocco D, Conte C, Palermo A, Maurizi AR, Pantano AL, Suraci C, Altomare M, Strollo R, Manfrini S, Pozzilli P, Schwartz AV, Napoli N. “Risk factors for fragility fractures in type 1 diabetes.” Bone. Vol. 125, pp: 194-199. Aug 2019. doi: 10.1016/j.bone.2019.04.017. PMID: 31059862

Maddaloni E, Coleman RL, Pozzilli P, Holman RR. “Long-term risk of cardiovascular disease in individuals with latent autoimmune diabetes in adults (UKPDS 85).” Diabetes Obes Metab 2019. Vol 21, n.6, pp: 2115-2122. doi: 10.1111/dom.13788. PMID: 31099472

Maddaloni E, Coleman RL, Agbaje O, Buzzetti R, Holman RR. “Time-varying Risk of Microvascular Complications in Latent Autoimmune Diabetes of Adulthood Compared with Type 2 Diabetes in Adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86)”. The Lancet. Diabetes & Endocrinology. Vol. 8, n. 3, pp: 206-215. Mar 2020. DOI: 10.1016/S2213-8587(20)30003-6. PMID: 32032540

Maddaloni E, Naciu AM, Mignogna C, Galiero R, Amendolara R, Fogolari M, Satta C, Serafini C, Angeletti S, Cavallo MG, Cossu E, Sasso FC, Buzzetti R, Pozzilli P; LADASAXADAPA study group. “Saxagliptin/dapagliflozin is non-inferior to insulin glargine in terms of β-cell function in subjects with latent autoimmune diabetes in adults: A 12-month, randomized, comparator-controlled pilot study”. Diabetes Obes Metab. 2024 Jan 31. doi: 10.1111/dom.15469. PMID: 38297915